PCM
NAGE

Perritt Capital Management’s Niagen Bioscience NAGE Stock Holding History

Perritt Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,000
Closed -$144K – 336
2025
Q2 		$144K Sell
10,000
-10,000
-50% -$98.7K 0.07% 171
2025
Q1 		$138K Sell
20,000
-20,000
-50% -$126K 0.08% 176
2024
Q4 		$212K Hold
40,000
– – 0.11% 156
2024
Q3 		$146K Hold
40,000
– – 0.08% 172
2024
Q2 		$109K Hold
40,000
– – 0.06% 187
2024
Q1 		$139K Buy
+40,000
New +$74K 0.08% 166

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Perritt Capital Management's NAGE Position: Q3 2025 in Review

Perritt Capital Management sold out of Niagen Bioscience (NAGE) in Q3 2025, closing a stake of 10,000 shares — an estimated $144K sold.

Perritt Capital Management first reported a position in NAGE in Q1 2024 and held it in 6 quarters. The position peaked at $212K in Q4 2024. 162 funds tracked by Wall St. Rank hold NAGE as of Q3 2025.

  • Perritt Capital Management reported no remaining Niagen Bioscience position as of Q3 2025 after selling out during the quarter.
  • Perritt Capital Management sold 10,000 Niagen Bioscience shares in Q3 2025, an estimated $144K.
  • Perritt Capital Management first reported a position in Niagen Bioscience in Q1 2024 and held it in 6 quarters.
  • Perritt Capital Management's Niagen Bioscience position peaked at $212K in Q4 2024.
  • 162 funds tracked by Wall St. Rank held Niagen Bioscience as of Q3 2025.

Based on Perritt Capital Management's 13F filing for Q3 2025, filed 17 Nov 2025.